Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Recurrence 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Carcinoma, Non-Small-Cell Lung 1C04.588.274.476.411.307 1Adenocarcinoma 1

Interventions

Gemcitabine 3Nivolumab 2temoporfin 1spartalizumab 1polysaccharide-K 1pembrolizumab 1nimotuzumab 1devimistat 1dalotuzumab 1bemarituzumab 1belinostat 1Transurethral Resection of Prostate 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiofrequency Ablation 1Oxaliplatin 1Morphine 1Methadone 1Leucovorin 1Ipilimumab 1Interviews as Topic 1Injections 1Immunotherapy 1Heavy Ion Radiotherapy 1Fluorouracil 1Erlotinib Hydrochloride 1Docetaxel 1Cryosurgery 1Cisplatin 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Adenocarcinoma × devimistat × Clear all
NCT01830322 2013-08-14

Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer

Cornerstone Pharmaceuticals

Phase 2 Withdrawn
Tumor-Agnostic

Adenocarcinoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡